title: Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis.
abstract: The therapeutic activity of rifamycin SV administered by the intra-articular route was evaluated in 52 children with juvenile rheumatoid arthritis (oligopolyarthritis). Each active joint was injected once a week for 10 weeks; thereafter patients were followed for 3-48 months. The number of active joints and joints with limitation of motion, the erythrocyte sedimentation rate (ESR) and C-reactive protein improved significantly at the end of the treatment cycle, with progressive improvement during the subsequent period of observation. At 48-month of follow-up, 78% of joints did not present signs of inflammation; and 66% of joints showed no functional limitations. Joints without radiological lesions at baseline and large joints responded best to the rifamycin treatment. Persistent knee effusions were reabsorbed completely in most cases during the treatment and within the first 6 months of follow-up. Recurrences of synovitis were observed in 7% of joints. De novo radiological lesions in initially undamaged joints occurred during the second year of follow-up in only 10% of patients. At 24 months, 62% of patients with oligoarthritis and 24% with polyarthritis showed complete remission in all affected joints and recovered movement in all those joints which had shown limitations at baseline. There was also a normalization of inflammatory indexes (ESR, C-reactive protein) and regression of general features of disease. Further long term studies are now required to confirm these promising preliminary results.
authors.affiliation: Rheumatology Unit, L. Sacco Hospital, Milan, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Caruso
authors.forename: N
authors.initials: N
authors.lastname: Principi
authors.forename: G
authors.initials: G
authors.lastname: D'Urbino
authors.forename: S
authors.initials: S
authors.lastname: Santandrea
authors.forename: L
authors.initials: L
authors.lastname: Boccassini
authors.forename: F
authors.initials: F
authors.lastname: Montrone
authors.forename: P C
authors.initials: PC
authors.lastname: Sarzi Puttini
authors.forename: A
authors.initials: A
authors.lastname: Bombaci
authors.forename: A
authors.initials: A
authors.lastname: Bozzato
authors.forename: V
authors.initials: V
authors.lastname: Azzolini
mesh_terms: D000293:Adolescent; D001171:Arthritis, Juvenile / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D002097:C-Reactive Protein / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007249:Inflammation; D007263:Infusions, Parenteral; D007596:Joints / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D012294:Rifamycins / Q000008:administration & dosage / Q000627:therapeutic use*; D013585:Synovitis / Q000188:drug therapy / Q000503:physiopathology; D013997:Time Factors
chemical_list: D012294:Rifamycins; D002097:C-Reactive Protein; C023808:rifamycin SV